PERT PRESENT | PERT CONSULTED | |||||
---|---|---|---|---|---|---|
Interventions and Patient Outcomes | Pre-PERT: n = 317 patients1 | Post-PERT: n = 369 patients1 | p-value2 | PERT NOT CONSULTED: n = 168 patients1 | PERT CONSULTED: n = 201 patients1 | p-value2 |
Systemic Anticoagulant | 308 (96.6%) | 355 (96.7%) | 0.9 | 156 (94.0%) | 199 (99.0%) | 0.007* |
Systemic Anticoagulation Medication | 1.0 | 0.02* | ||||
Apixaban | 4 (1.3%) | 7 (2.0%) | 3 (1.9%) | 4 (2.0%) 0 | ||
Argatraban | 0 (0%) | 1 (0.3%) | 1 (0.6%) | (0%) | ||
Dalteparin | 16 (5.2%) | 3 (0.8%) | 1 (0.6%) | 2 (1.0%) | ||
Edoxaban | 1 (0.3%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
Enoxaparin | 54 (18%) | 106 (30%) | 38 (24%) | 68 (34%) | ||
Other | 0 (0%) | 1 (0.3%) | 0 (0%) | 1 (0.5%) | ||
Rivaroxaban | 11 (3.6%) | 10 (2.8%) | 4 (2.5%) | 6 (3.0%) | ||
Unfiltered Heparin | 217 (71%) | 228 (64%) | 110 (70%) | 118 (59%) | ||
Warfarin | 2 (0.7%) | 1 (0.3%) | 1 (0.6%) | 0 (0%) | ||
Time to Therapeutic AC (Hours) | 8 (6, 20) | 8 (6, 22) | 0.6 | 8 (6, 23) | 8 (6, 15) | 0.3 |
Number of Procedures | 66 (20.8%) | 42 (11.4%) | 0.01* | 16 (9.5%) | 26 (12.9%) | 0.4 |
Procedural Intervention | ||||||
Catheter-Directed Lysis | 15 (4.7%) | 2 (0.5%) | < 0.001* | 1 (0.6%) | 1 (0.5%) | > 0.9 |
IVC Filter | 42 (13.2) | 24 (6.5%) 1 | 0.003* | 13 (7.8%) | 11 (5.5%) 1 | 0.4 |
Surgical Intervention | 4 (1.3%) | (0.3%) | 0.2 | 0 (0.0%) | (0.5%) | > 0.9 |
Thromboaspiration | 5 (1.6%) | 15 (4.1%) | 0.050 | 2 (1.2%) | 13 (6.5%) | 0.015* |
Systemic Thrombolysis | 20 (6.3%) | 19 (5.2%) | 0.5 | 4 (2.4%) | 15 (7.5%) | 0.030* |
Hospital Length of Stay (days) | 6 (2, 11) | 6 (3, 12) | 0.12 | 9 (4, 18) | 4 (2, 8) | < 0.001* |
ICU Length of Stay (days) | 0 (0, 4) | 0 (0, 4) | 0.6 | 2 (0, 7) | 0 (0, 2) | < 0.001* |
30-Day Mortality | 0.78 | 0.0024* | ||||
Alive at 30 Days | 276 (87.0%) | 321 (87.0%) | 132 (80%) | 189 (94%) | ||
Dead at 30 Days | 37 (12.0%) | 43 (12.0%) | 33 (20%) | 10 (5.0%) | ||
Unknown | 3 (1.9%) | 3 (0.8%) | 1 (0.6%) | 2 (1.0%) | ||
Goals of Care Precluded PERT Consult | – – | – | 12 (7.1%) N/A – |